Reducing the Global Burden of Dementia: The First Effective Treatment for Alzheimer’s Disease

Everyone knows someone who’s survived cancer. But no one knows anyone who’s survived Alzheimer’s—until now. Alzheimer’s disease is a global pandemic and the third leading cause of death in the United States. Of the 326 million Americans currently living, approximately 45 million will develop Alzheimer's disease during their lifetimes unless effective prevention programs are instituted. The 99 percent failure rate of Alzheimer’s drug trials underscores both the area of greatest biomedical failure and the need for a more complete understanding of the drivers (i.e., the root causes) of the disease. Despite these alarming statistics, it has now been demonstrated that early stage Alzheimer's and its precursors, mild cognitive impairment (MCI) and subjective cognitive impairment (SCI), can be prevented and in some cases reversed. 

Join Dale Bredesen as he presents a novel programmatic approach that identifies and targets the multiple contributors to cognitive decline. Based on his findings from over 30 years of research into the mechanisms of neurodegenerative diseases, this approach led to the first published reports of the reversal of cognitive decline. Currently, over 3,000 patients use the protocol described in these initial reports, with success that has not been described previously.

MLF Organizer: Adrea Brier

MLF: Health & Medicine